In a move aimed at making treatment more affordable, the Central Government has brought 39 widely used medicines for diabetes, hypertension, heart ailments and other chronic diseases under price control, offering relief to millions of patients across the country.
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for these medicines under the provisions of the Drugs (Prices Control) Order, 2013, preventing manufacturers from charging beyond the prescribed rates.
The latest list largely includes medicines used for long-term treatment of lifestyle diseases such as diabetes, high blood pressure and cardiovascular disorders, which require uninterrupted medication for years. The decision is expected to reduce the monthly financial burden on patients and families managing chronic illnesses.
Apart from medicines for non-communicable diseases, the NPPA has also fixed the retail price of Calcium and Vitamin D3 tablets at Rs 8.93 per tablet, inclusive of GST. The supplements are commonly prescribed to senior citizens, women and patients suffering from deficiencies affecting bone health.
The regulator has also revised the retail price of Anti-Rabies Immunoglobulin injection to Rs 119.48, making post-exposure treatment for suspected rabies cases more affordable. The injection plays a crucial role in emergency treatment following animal bites and is administered along with anti-rabies vaccines to provide immediate protection against the virus.
Under the revised pricing framework, pharmaceutical companies have been instructed to immediately implement the new rates and ensure that the updated Maximum Retail Price (MRP) is reflected on medicine packaging. Officials clarified that the revised prices will apply only to the formulations and strengths specifically notified by the NPPA, and not to all medicines used for the treatment of these diseases.
Healthcare experts have welcomed the decision, noting that medicines constitute one of the largest components of out-of-pocket healthcare expenditure in India. With cases of diabetes, hypertension and heart disease rising steadily, affordable access to essential medicines remains critical for ensuring treatment adherence and preventing complications.
The NPPA said the prices were determined after evaluating manufacturing costs, market trends and other relevant factors, while balancing the interests of patients and pharmaceutical manufacturers.
Key points for consumers
- Manufacturers cannot sell the notified medicines above the retail prices fixed by the NPPA.
- The revised prices have come into effect immediately.
- Pharmaceutical companies are required to update MRPs on product packaging.
- The price cap applies only to the specific formulations and strengths covered under the notification.
The latest move is expected to provide much-needed financial relief to patients dependent on lifelong medication and strengthen efforts to make healthcare more affordable and accessible across the country.